Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours | News Direct

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours

Clearmind Medicine Inc
News release by Clearmind Medicine Inc

facebook icon linkedin icon twitter icon pinterest icon email icon Vancouver, Canada | February 26, 2024 10:37 AM Eastern Standard Time

 

Clearmind Medicine Inc CEO Dr. Adi Zuloff-Shani joined Steve Darling from Proactive to announce a significant milestone for the company: the granting of divisional patent approval by the China National Intellectual Property Administration (CNIPA). This latest patent approval solidifies Clearmind's patent protection for its flagship molecule and further establishes its extensive intellectual property (IP) protection in the psychedelic space.

Clearmind's IP portfolio now encompasses fifteen utility patent families, including patents and applications with method of use and composition of matter claims. This includes 24 pending patent applications and 27 granted patents in key jurisdictions such as the US, Europe, China, and India. The company's robust IP portfolio positions it as a leader in the development of innovative treatments in the psychedelic field.

Dr. Zuloff-Shani provided insights into Clearmind's flagship molecule, MEAI, which has shown promise in reducing the desire to consume alcoholic beverages while inducing a slight euphoric, alcohol-like experience. This treatment targets Alcohol Use Disorder, a prevalent condition characterized by an individual's inability to control their alcohol consumption despite negative consequences. MEAI also holds potential in addressing binge drinking, offering hope for individuals struggling with this harmful addiction.

Clearmind plans to commence clinical trials for alcohol use disorder, expand their IP portfolio, and explore M E's potential in treating obesity. With collaborations with esteemed institutions like Johns Hopkins and Yale, Clearmind aims to revolutionize addiction treatment and offer innovative solutions to societal challenges. Stay tuned for their exciting developments in 2024.

 

Contact Details

 

Proactive North America

 

Proactive North America

 

+1 604-688-8158

 

NA-editorial@proactiveinvestors.com

project media

Tags

HealthTherapeuticsPsychadelicsDrug developmentClinical StudyBinge